Literature DB >> 3989336

Measurement of 2',5'-oligoadenylate synthetase in patients receiving interferon-alpha.

J A Merritt, E C Borden, L A Ball.   

Abstract

The interferon-induced intracellular enzyme, 2',5'-oligoadenylate (2,5A) synthetase, was measured in extracts of Ficoll-purified human peripheral mononuclear cells from 28 normal healthy individuals and 14 patients receiving injections of interferon-alpha. Basal and stimulated levels could be measured reproducibly in 2 X 10(6) cells. In both groups, mononuclear cell levels of 2,5A synthetase varied widely, but measurements were reproducible in each individual. In most instances, increases in enzyme activity were detected within 8 h of interferon-alpha administration. Elevated levels persisted for at least 24 h and were maintained with daily treatment. In two of the 14 patients, the enzyme level failed to respond to multiple interferon injections. Interestingly, these two patients had pretreatment enzyme levels that were markedly elevated relative to those of a healthy population. Measurement of 2,5A synthetase levels is a valuable addition to clinical interferon studies, since the results may help to resolve questions of the optimal dose, route, and schedule of interferon administration.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3989336     DOI: 10.1089/jir.1985.5.191

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  11 in total

1.  Induction and measurement of 2',5'-oligoadenylate synthetase in Madin-Darby bovine kidney cells and in cattle.

Authors:  E C Short; R W Fulton
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

2.  Posttranscriptional regulation of c-myc proto-oncogene expression and growth inhibition by recombinant human interferon-beta ser17 in a human colon carcinoma cell line.

Authors:  D Chatterjee; T M Savarese
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Molecular signatures of peripheral blood mononuclear cells during chronic interferon-α treatment: relationship with depression and fatigue.

Authors:  J C Felger; S W Cole; T W W Pace; F Hu; B J Woolwine; G H Doho; C L Raison; A H Miller
Journal:  Psychol Med       Date:  2011-12-09       Impact factor: 7.723

4.  Establishment of a nonradioactive assay for 2'-5' oligoadenylate synthetase and its application in chronic hepatitis C patients receiving interferon-alpha

Authors:  Wen-Bin Tong; Chun-Ying Zhang; Bai-Fang Feng; Qi-Min Tao
Journal:  World J Gastroenterol       Date:  1998-02       Impact factor: 5.742

5.  A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.

Authors:  J H Schiller; B Storer; D M Paulnock; R R Brown; S P Datta; P L Witt; E C Borden
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

6.  Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-alpha 2.

Authors:  S P Robinson; D Goldstein; P L Witt; E C Borden; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1990-02       Impact factor: 4.872

7.  Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C.

Authors:  N P Lam; D Pitrak; R Speralakis; A H Lau; T E Wiley; T J Layden
Journal:  Dig Dis Sci       Date:  1997-01       Impact factor: 3.199

8.  Detection of elevated levels of 2-5A synthetase in serum from children with various infectious diseases.

Authors:  H Sugino; I Mitani; M Koike; T Kodama; J Sokawa; H Sawai; K Ishibashi; M Itoh; S Watanabe; Y Sokawa
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

9.  Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon.

Authors:  G T Spear; D M Paulnock; R L Jordan; D M Meltzer; J A Merritt; E C Borden
Journal:  Clin Exp Immunol       Date:  1987-07       Impact factor: 4.330

10.  Decreased interferon binding capacity of peripheral blood mononuclear cells during interferon treatment of chronic hepatitis B with special reference to (2'-5') oligoadenylate synthetase activity.

Authors:  M Shindo; A Iwata; T Okuno; M Matsumoto; M Takeda; K Arai; Y Sokawa
Journal:  Gastroenterol Jpn       Date:  1989-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.